CAMP and colitis: Additionally, we observed that endogenous production of hCAP18, as induced by DNA vaccine delivery, strengthened the protective effects of this bacterium; mice treated with LL-Probi-H1:hCAP18 were more protected from developing symptoms of colitis than those who were treated with LL-pSEC:hCAP18.